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Cardiovascular disorders are common in HIV-1 infected persons in Africa and presentation
is often insidious. Development of screening algorithms for cardiovascular disorders appro-
priate to a resource-constrained setting could facilitate timely referral. Cardiothoracic ratio
(CTR) on chest radiograph (CXR) has been suggested as a potential screening tool but little
is known about its reproducibility and stability. Our primary aim was to evaluate the stability
and the inter-observer variability of CTR in HIV-1 infected outpatients. We further evaluated
the prevalence of cardiomegaly (CTR0.5) and its relationship with other risk factors in this
population.
Methodology
HIV-1 infected participants were identified during screening for a tuberculosis vaccine trial
in Khayelitsha, South Africa between August 2011 and April 2012. Participants had a digital
posterior-anterior CXR performed as well as history, examination and baseline observa-
tions. CXRs were viewed using OsiriX software and CTR calculated using digital callipers.
Results
450 HIV-1-infected adults were evaluated, median age 34 years (IQR 30–40) with a CD4
count 566/mm3 (IQR 443–724), 70% on antiretroviral therapy (ART). The prevalence of
cardiomegaly was 12.7% (95% C.I. 9.6%-15.8%). CTR was calculated by a 2nd reader for
113 participants, measurements were highly correlated r = 0.95 (95% C.I. 0.93–0.97) and
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agreement of cardiomegaly substantial κ = 0.78 (95% C.I 0.61–0.95). CXR were repeated
in 51 participants at 4–12 weeks, CTR measurements between the 2 time points were
highly correlated r = 0.77 (95% C.I 0.68–0.88) and agreement of cardiomegaly excellent
κ = 0.92 (95% C.I. 0.77–1). Participants with cardiomegaly had a higher median BMI (31.3;
IQR 27.4–37.4) versus 26.9; IQR 23.2–32.4); p<0.0001) and median systolic blood pres-
sure (130; IQR 121–141 versus 125; IQR 117–135; p = 0.01).
Conclusion
CTR is a robust measurement, stable over time with substantial inter-observer agreement.
A prospective study evaluating utility of CXR to identify cardiovascular disorder in this popu-
lation is warranted.
Introduction
The rising impact on health of non-communicable diseases (NCD) (mainly cardiovascular dis-
ease, cancer, diabetes and chronic respiratory disease) in low and middle income countries
(LMIC) is of great concern and implementation of measures to curb this is high on the global
health agenda. Co-ordinated strategies that strengthen health systems and the capacity of pri-
mary care to prevent and detect these chronic diseases early are a key component of the
response[1]. In sub-Saharan Africa (SSA) the HIV-1 epidemic directly impacts on NCD bur-
den. HIV-1 predisposes to cardiovascular disorders through the direct effects of HIV-1, HIV-1
related immune-activation and inflammation, opportunistic infections, drug toxicity and meta-
bolic consequences of antiretroviral therapy (ART) in addition to other cardiovascular risk fac-
tors that disproportionately affect this population[2, 3].
In a recent study characterising presentations of 518 HIV-1 infected adults to a tertiary car-
diac unit in South Africa, cardiomyopathy was the commonest diagnosis accounting for 38%
of presentations (structural dilatation was present in over 50%) followed by pericarditis/peri-
cardial effusion in 24%. 8% of patients had evidence of pulmonary hypertension and of note,
the majority of patients were on ART at presentation[4]. In SSA and similar resource-limited
settings, access to such specialist cardiology services is constrained and misdiagnosis in pri-
mary care may contribute to delayed referral and advanced presentation explaining in part, the
poor prognosis associated with HIV-associated cardiac disease. Although early use of ART is
believed to have resulted in a reduced incidence of these cardiac complications to an extent [5],
screening for cardiac disease is crucial to allow for early detection and appropriate specific ther-
apy in order to prevent progression and improve survival.
Simple, cost effective screening tools and strategies that assist timely referral of these
patients for appropriate assessment are needed. Cardiothoracic ratio (CTR) on chest radio-
graph (CXR), the ratio of maximal cardiac diameter to internal thoracic diameter, with
CTR0.5 usually considered abnormal, has previously been proposed as a potential screening
tool in this setting[6, 7]. In a tertiary referral hospital in Botswana, 106 HIV-1 infected patients
(median CD4 299, 54% on ART) with cardiomegaly on CXR (all of whom had CTR0.53)
underwent echocardiography, 99% had an abnormal echocardiogram (41% cardiomyopathy,
29% pericarditis, 9% right heart failure) [6]. A second study set in a tertiary referral hospital in
South Africa evaluated 41 HIV-1 infected individuals with TB pericarditis and pericardial
effusions> 10mm and demonstrated that all had CTR0.55[7]. However, such studies are
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prone to referral bias and therefore cannot be used to determine sensitivity or specificity of par-
ticular CTR cut offs, this would necessitate evaluation in a variety of asymptomatic persons in
primary care settings.
Chest radiography has been a widely available investigation for decades and cardiomegaly has
been shown repeatedly to be predictive of cardiovascularmortality in several large studies[8, 9].
However CTR has been shown to have a limited role as a screening tool for left ventricular failure
as approximately a third of patients with Left Ventricular Ejection Fraction (LVEF) <0.35 will
have a CTR< 0.5[10]. This is in part as the left ventricle is not the primary contributor to the
cardiac shadow and not all those with left ventricular failure will have enlarged ventricles, as a
result, correlation of CTR with LVEF can be weak[10–12]. Correlation of transverse diameter of
the heart shadow on CXRwith Left Ventricular End Diastolic Volume (LVEDV) has been found
to be good [13] and in addition CTR correlates better with right ventricular and atrial size than
for left ventricular size[14]. CTRmay therefore bemore useful in HIV-1 infected population
especially in SSA as a screening tool for the common cardiac presentations in this setting rather
than a narrow screen for left ventricular dysfunction, as dilated cardiomyopathy and pulmonary
artery hypertension and pericardial effusions are more likely to cause elevated CTR.
Before CTR can be evaluated for its predictive value as a screening tool for cardiovascular
abnormalities in HIV-1, as for any test, it is important to first establish if CTR is a stable and
reproducible measure. In particular for an imaging test of this nature, variability can be created
through biological factors such as cardiac motion and depth of inspiration, technical factors
such as patient positioning or machine characteristics and inter-observer variability[15]. All
these factors could affect the reproducibility of CTRmaking it an unsuitable screening tool.
As a preliminary evaluation of CTR to inform future studies in this area, the primary aim of
our study was to evaluate the inter-observer variability and the reproducibility of CTR in this
population over time.
Materials and Methods
The study adhered to International Conference on Harmonisation GoodClinical Practice
guidelines, and was approved by the University of Cape Town's Faculty of Health Sciences
Human Research Ethics Committee (REC 001/2010). All participants provided written
informed consent.
Participants were identified betweenAugust 2011 and April 2012 during screening for a
phase IIB tuberculosis vaccine trial[16]. All participants were resident in Khayelitsha, a peri-
urban township of Cape Town, South Africa. Screening investigations included a digital poste-
rior-anterior CXR (PA-CXR), 2 sputum cultures forMycobacterium tuberculosis (Mtb), as well
as history, examination, baseline observations and basic demographic details. As per-protocol,
a proportion of the participants had repeat CXR performed after approximately 6–12 weeks to
ensure no progressive parenchymal lesions thought to be due to either active or inactive tuber-
culosis. All study data were collected on electronic case report forms (web-based platform) and
stored on a dedicated secure central database.
Inclusion criteria for the study were healthy HIV-1-infected patients, aged 18–50 years
either established on ART or ART-naïve with CD4 300/mm3. Participants were excluded if
they had culture positive sputum forMycobacterium tuberculosis, if less than 8 posterior ribs
were visible on CXR or if mediastinal shift was present from fibrosis relating to previous TB.
PA-CXR in full inspiration with arms pronated were performed at the beginning of the
study on a Delft Odelca DR and then subsequently on a Phillips Essenta DR at 125kV with
source to image distance 180cm. Digital images were uploaded using OsiriX software and
viewed on a 2 Megapixel screen in low ambient light.
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CTR was calculated as ratio of maximal width of cardiac shadow to maximal internal tho-
racic width visible on CXR using digital callipers (Fig 1). A CTR 0.50 was considered cardio-
megaly. A second reader independently evaluated 113 of 450 (25%) baseline CXR
(systematically identified as every 4th CXR chronologically) without knowledge of primary
readers results. Sample size was determined using methodologydescribed by Cantor et al [17].
Assuming 50% inter-reader agreement and a 20% relative error margin a sample size of at least
100 was required to achieve power of 80% at α = 0.05. 51 participants had repeat CXR as per-
protocol, CTR for the repeat CXR was evaluated by the primary reader without reference to the
initial CXR.
Statistical analysis plan
The Shapiro-Wilk test was used to establish normality of data. Correlation of CTRmeasure-
ments was then calculated by Pearson’s or Spearman’s coefficients as appropriate. Agreement
Fig 1. Method for determining Cardiothoracic Ratio. Digital Posterior-Anterior Chest Radiograph (CXR) with maximal
cardiac diameter in red and maximal thoracic diameter in green. Cardiothoracic ratio (CTR) is 0.57.
doi:10.1371/journal.pone.0163490.g001
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between observers as to which participants had cardiomegaly (CTR 0.50) was determined
using the Kappa test statistic and 95% confidence intervals calculated. Non-paired, non-
parametric data were compared usingWilcoxon rank sum (Mann-Whitney U) test and
parametric data using student’s t-test. Proportions were compared by χ2 test. Risk factors asso-
ciated with cardiomyopathy were analysed using logistic regression. The model was built man-
ually using a bidirectional stepwise regression approach, sequentially including variables with a
p value<0.20 in univariate analyses. All data was analysed using STATA 12.0 (StataCorp, Col-
lege Station, TX, USA).
Results
483 participants had CXR available, 20 were excluded, as culture positive for tuberculosis, 5
excluded with suboptimal CXR and 8 had no clinical information available. 450 HIV-
1-infected adults were included with median age 34 years (IQR 30–40), 86% female, median
CD4 count 566 (IQR 443–724) with 70% prescribedART. All participants were Black African,
specific ethnicity was not inquired about, but at last census 97% of Khayelitsha residents were
Xhosa. The prevalence of cardiomegaly in this group was 12.7% (95% C.I. 9.6%-15.8%) with
3.1% having CTR 0.53 and 1.8% having CTR 0.55.
Inter-reader correlation
CTR was calculated by a 2nd reader for 113 of 450 participants. The independentmeasure-
ments of CTR by the 2 readers were highly correlated r = 0.95 (95% C.I. 0.93–0.97) p<0.0001.
Correlation of thoracic width beingmarginally better than cardiac width r = 0.95 (95% C.I.
0.93–0.97) versus r = 0.93 (95% C.I. 0.90–0.95) respectively. Agreement between the 2 readers
in classification of cardiomegaly (CTR0.5) by kappa statistic was substantial κ = 0.78 (95% C.
I 0.61–0.95) (Fig 2).
Reproducibility of CTR
CXRwere repeated in 51 participants after a median of 48 days (IQR 40–72), CTRmeasure-
ments performed by reader 1 at the 2 time points were highly correlated r = 0.77 (95% C.I
0.68–0.88) and agreement of cardiomegaly (CTR0.5) was excellent κ = 0.92 (95% C.I. 0.77–1)
(Fig 2). Of the 51 with repeat CXR, 12 participants had repeat CXR performed on a different x-
ray machine, and CTR remained highly correlated r = 0.89 (95% C.I 0.66–0.97) (Fig 2).
Factors associated with CTR0.50
Table 1 shows baseline characteristics of patients categorised by cardiomegaly using a CTR
cut-off of 0.50. There was no difference in the prevalence categorising by gender or ART status.
The median age was higher in patients with cardiomegaly compared to persons without (36.5
years; IQR (32–41) vs. 34 years; IQR (30–39); p = 0.04). Patients with cardiomegaly had a
higher median bodymass index (BMI) (31.2 kg/m2; IQR 27.3–38.2 versus 26.9 kg/m2; IQR
23.2–32.4; p<0.0001) and had higher systolic blood pressures (130mmHg; IQR 121–141 versus
125mmHg; IQR 117–135; p = 0.01). Comparing existing co-morbidities risk factors, there was
a higher prevalence of hypertension (16.7% vs. 5.2%, p = 0.001) and diabetes mellitus (5.6% vs.
1.3%, p = 0.029) in participants with cardiomegaly (Table 1). Multivariate logistic regression
was subsequently carried out and a model including BMI> 25, history of stroke, Diabetes mel-
litus and observedor reported hypertension as explanatory variables were found to best predict
cardiomegaly (Table 2). Age was found to be associated with hypertension and inclusion did
not improve the model.
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Discussion
We have shown that correlation of CTRmeasurement between readers was extremely high and
that there was a substantial agreement in the classification of cardiomegaly (CTR0.50). Fur-
thermore we have demonstrated that over a period of 6–10 weeks, CTR is a stable measure-
ment with high correlation and excellent agreement in classification of cardiomegaly when
Fig 2. Correlation between timepoints and readers. a. Scatter plot showing correlation of cardiothoracic Ratio (CTR)
for 51 participants with repeat chest radiograph (CXR) 4–12 weeks apart read by a single reader. Top left and bottom right
quadrants represent differences in classification of cardiomegaly between reads. b. Scatter plot showing correlation of
CTR for 113 participants determined independently by 2 readers. Top left and bottom right quadrants represent
differences in classification of cardiomegaly between readers.
doi:10.1371/journal.pone.0163490.g002
Table 1. Association of variable and risk factors with cardiomegaly—Table compares participants
with and without cardiomegaly for a number of variables and risk factors. Med = median,
IQR = Interquartile Range, VL = viral load.
Variable CTR0.50: n = 57 CTR <0.50: n = 393 p-value
Age (years)—Med(IQR): n = 450 36 (32–41) 34 (30–39) 0.04
BMI (kg/m2)—Med(IQR): n = 441 31.3 (27.4–37.4) 26.9 (23.2–32.4) <0.0001
Systolic BP (mmHg)—Med(IQR): n = 437 130 (121–141) 125 (117–135) 0.01
Pulse (bpm)—Med(IQR): n = 441 69 (65–77) 72 (66–81) 0.12
Diastolic BP (mmHg)—Med(IQR): n = 437 81 (75–91) 79 (72–87) 0.08
CD4 count (/mm3)—Med (IQR): n = 449 639 (461–757) 554 (442–720) 0.22
VL if not on ART (Copies/mL)—Med (IQR): n = 135 9983 (2703–18011) 7734 (1955–25401) 0.24
Days since HIV diagnosis—Med (IQR): n = 437 1937 (1020–3291) 1934 (973–2869) 0.56
Reported hypertension (%): n = 439 16.7% 5.2% 0.001
Diabetes mellitus (%): n = 438 5.6% 1.3% 0.029
History of stroke (%): n = 439 1.9% 0.26% 0.104
On ART (%): n = 450 71.9% 69.7% 0.734
Current or Ex-Smoker (%): n = 446 10.9% 22.0% 0.057
Current Alcohol consumption (%): n = 446 18.2% 27.6% 0.137
Female (%): n = 450 89.5% 86.0% 0.471
doi:10.1371/journal.pone.0163490.t001
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measured by the same reader. CTR is therefore a robust and reproducible measurement and it
would be appropriate to further evaluate its utility as a screening tool for cardiovascular abnor-
malities in this population.
Our finding that inter-observer agreement for CTR is high is in keeping with previous find-
ings[18, 19]. However to our knowledge, this is the first study to show that CTR is stable over
time, suggesting that cardiac motion and subtle alterations in positioning and depth of inspira-
tion do not have a significant impact on CTR. In addition to this, we have shown that CTR is
reproducible using different X-Ray machines.
We found 12.7% of our HIV-1 infected outpatient population of predominantly women
aged 30–40 had evidence of cardiomegaly. Those with cardiomegaly were more likely to have
elevated BMI and systolic blood pressure, in keeping with previous studies[9]. We did not find
any differences in prevalence of cardiomegaly between those on ART and those that were
ART-naïve. However, our study was not specifically designed to address this and duration and
type of ART may have an impact on cardiovascular disorders.
Performance characteristics of CTR as a screening tool to identify HIV-associated heart dis-
ease have yet to be defined.However, a recent systematic review evaluating CTR to predict LV
dilatation on echocardiogram looked at 6 studies (none of which focusedon HIV or an African
setting) with a total of 466 patients, CTR0.5 had sensitivity 83.3%, specificity 42.5%, positive
predictive value 43.5% and negative predictive value 82.7% for LV dilatation on echocardiogram
[20]. The high sensitivity and negative predictive value are important characteristics of a screen-
ing test. Although those with LV dilatation and normal CTRmight be missed by the use of CXR
screening, elevated CTR has been shown to be a predictor of mortality in those with dilated car-
diomyopathy suggesting those at highest risk of mortality would likely be identified[21]. Low
specificity and positive predictive value increase number needed to screen, whichmay impact
on resources and patient anxiety. However in the context of HIV associated cardiac disease a
number or other important conditions may lead to increasedCTR in particular pericardial effu-
sion and pulmonary hypertension as well as conditions not specifically associated with HIV but
common in SSA such as rheumatic heart disease and hypertensive heart disease. This would
result in an improvement in positive predictive value for significant cardiac disorders.
It is also possible that there may be certain groups where sensitivity of CTRmay be reduced,
for example those with chronic obstructive pulmonary disease (COPD), usually secondary to
smoking, often have increased thoracic diameter and therefore a reduced CTR. In our study we
did not find a significant difference in prevalence of cardiomegaly between smokers and non-
smokers, although our participants were relatively young and therefore COPD would be
expected to be uncommon. Ultimately, CTR alone may not have the desired sensitivity and
specificity required to screen for cardiovascular disorders in all populations. It may be that
incorporation of additional measures such as electrocardiogram, symptom screen or evaluation
of exercise tolerance into a screening algorithm are required to optimize performance. Further
studies will be needed to investigate this.
Our study has several limitations; we only evaluated a single approach to measurement of
CTR.Measurement of CTR is not standardised with several approaches described for both
Table 2. Results of multivariable logistic regression.
Variable p-value Odds Ratio (95% C.I)
BMI (>25kg/m2) <0.001 5.8 (2.2–15.3)
Hypertension (observed or reported) 0.004 2.4 (1.3–4.5)
History of stroke 0.031 26.7 (1.4–529.7)
Diabetes mellitus 0.047 5.6 (1.0–30.3)
doi:10.1371/journal.pone.0163490.t002
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measurement of cardiac and thoracic width and furthermore other measurements of cardiac
size on CXR are possible. In the originalmethod describedby Danzer, maximal thoracic width
was used but since then others have used thoracic width at the level of the right hemi-dia-
phragm, left hemi-diaphragm or right costophrenic angle[22, 23], thoracic diameter can vary
up-to 3.9% depending on methodologyused.We chose to measure maximal thoracic diameter
and therefore may have slightly underestimated CTR[18]. Although CTR is the most widely
usedmeasurement of cardiac size that can be made on CXR, it is not the only usefulmeasure-
ment. Transverse diameter of the heart shadow on CXR alone has been shown to be more
highly correlated (r = 0.75) with LVEDV, determined by cardiac MRI, than CTR (r = 0.46)[13].
A more complex calculation of heart volume can also be made using a lateral in addition to a
PA view, although this is a slightly more sensitive technique to identify ventricular hypertrophy
at autopsy compared with CTR (65% vs 57%)[24].
We did not specifically explore factors that might affect inter-observer variability or repro-
ducibility of the CTR. It is possible patient factors such as presence of epicardial fat pad or sig-
nificant breast shadow may obscure the cardiac border affecting this. However technical
factors may bemore important. Our study was conducted in a trial setting and all CXR were
performed to a strict standardized operating procedure (SOP) with radiographs of poor techni-
cal quality repeated. In a clinical setting there may be greater technical variation between radio-
graphs, which might be expected to affect stability of CTR, as rotation and changes in
inspiratory effort might affect reproducibility. In addition, CXR in our study were digital,
which allows the reader to optimize contrast of image on a screen prior to takingmeasure-
ments. In conventional radiography this cannot be done and poorly penetrated filmsmay
result in obscuring of the cardiac shadow, which may contribute to uncertainly over the maxi-
mal cardiac diameter and result in increased inter-observer variability.
We showed that CTR was reproducible on a repeated image and hence also showed it was
stable over time. However, the time period betweenCXR (median 48 days) was determined by
the protocol of the vaccine trial this study was embeddedwithin and so we were unable to eval-
uate whether CTR would be stable over longer periods of time.
Conclusion
Screening algorithms to identify HIV-1-infected persons at high risk of cardiovascular disease
or needing referral for specialist investigation that can be implemented in resource limited set-
tings care need to be developed. Revisiting how CTRmight be useful in this context as a non-
invasive marker for identifying structural cardiac abnormalities in HIV-1-infected populations
seems warranted. We have shown CTR is a robust and reproducible measure that can be taken
forward into future studies.
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